Home › Compare › SGTSY vs ABBV
SGTSY yields 200.00% · ABBV yields 3.06%● Live data
📍 SGTSY pulled ahead of the other in Year 1
Combined, SGTSY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SGTSY + ABBV for your $10,000?
Singulus Technologies AG, together with its subsidiaries, develops, builds, and sells machinery in the areas of vacuum deposition, surface engineering, wet chemical, and thermal processing technologies worldwide. The company operates through three segments: Solar, Life Science, and Semiconductor. The Solar segment develops production solutions to manufacture solar cell concepts, including heterojunction, interdigitated back contact, and tunnel oxide passivated contacts for crystalline and thin-film solar cells. The Life Science segment offers product solutions for medical technology, decorative coating, and data storage; and develops an integrated product line DECOLINE II, inline vacuum cathode sputtering machine POLYCOATER, and MEDLINE for application in medical technologies. This segment also provides data storage machines for the production of optical disc formats comprising of CD, DVD, dual layer Blu-ray, and Ultra HD Blu-ray discs. The Semiconductor segment supplies special purpose machines and machine platforms, such as TIMARIS and ROTARIS for use in magneto resistive random access memory, sensors, power controllers, and microelectromechanical systems. Singulus Technologies AG was founded in 1995 and is headquartered in Kahl am Main, Germany.
Full SGTSY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.